Phase 1 Study of Rezatapopt, a p53 Reactivator, in TP53 Y220C–Mutated Tumors | NEJM Rezatapopt is an investigational, first-in-class, oral, selective p53 reactivator that specifically binds to Y220C-mutated p53, which stabilizes p53 in its wild-type conformation and restores its f...

Rezatapopt for TP53 Y220C–Mutated Tumors. Game changer! #Y220C #Rezatapopt #PYNNACLE @nejm.org

Acquired on-target alterations drive clinical resistance to p53-Y220C reactivators Abstract. The tumor suppressor TP53 is the most frequently altered gene in cancer, and the Y220C hotspot, found in 1.8% of TP53-mutant tumors, creates a druggable cavity that destabilizes p53. Rezatap...

Happy to report the first clinical evidence revealing how tumors develop resistance to p53-Y220C reactivators out today at Cancer Discovery @aacrjournals.bsky.social @mgbresearch.bsky.social @harvardmed.bsky.social @oncoalert.bsky.social @oncodaily.bsky.social #CorcoranLab #Rezatapopt #PYNNACLE